A Clinical Study of T3011 in Subjects With Advanced Melanoma

This clinical study evaluated the tolerability, safety and preliminary efficacy of T3011 in subjects with advanced melanoma.

Trial Details

NCT ID
NCT06214156
Phase
PHASE1 / PHASE2
Sponsor
Shanghai Pharmaceuticals Holding Co., Ltd
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • T3011
Locations (sample)
  • Beijing, China|39.9075,116.39723
  • Bengbu, China|32.94083,117.36083
  • Changchun, China|43.88,125.32278
  • Chengdu, China|30.66667,104.06667
  • Fuzhou, China|26.06139,119.30611

Key Eligibility Criteria

  • Subjects with advanced melanoma;
  • At least one measurable lesion;
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1;
  • Expected survival \> 12 weeks;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →